Jeffrey A. Cohen, MD

Longer-term treatment with ofatumumab led to lessening of disability progression and slowing of brain volume loss, according to Jeffrey A. Cohen, MD, in this Healio video.

A novel allogeneic Epstein-Barr virus-targeted T-cell immunotherapy in early development was well-tolerated and led to sustained disability improvements in patients with progressive forms of MS, researchers reported at MSVirtual2020.

Treatment with masitinib, a first-in-class tyrosine kinase inhibitor, led to significant improvement in Expanded Disability Scale Status, or EDSS, for patients with MS, according to findings presented at MSVirtual2020.

In this video from MSVirtual2020, Jeffrey Cohen, MD, professor of medicine (neurology) at Cleveland Clinic Lerner College of Medicine and ACTRIMS president, provides an overview of what to expect from the meeting. The 8th Joint ACTRIMS-ECTRIMS Meeting is being held from Sept. 11-13, 2020, in a virtual format because of the COVID-19 pandemic.